WHO Recommends Against Roche, GSK''s COVID-19 Therapies Rendering Them Obsolete
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. WHO experts said they strongly advised against using GSK plc (NYSE: GSK ) | Vir Biotechnology Inc''s (NASDAQ: VIR ) sotrovimab and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) | Roche Holdings AG''s (OTC: RHHBY ) antibody cocktail casirivimab-imdevimab. The recommendation comes as part of a suite of recommendations published in the British Medical Journal . The two therapies designed to work by binding to the … Full story available on Benzinga.com
WHO Recommends Against Roche, GSK''s COVID-19 Therapies Rendering Them Obsolete
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. WHO experts said they strongly advised against using GSK plc (NYSE: GSK ) | Vir Biotechnology Inc''s (NASDAQ: VIR ) sotrovimab and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) | Roche Holdings AG''s (OTC: RHHBY ) antibody cocktail casirivimab-imdevimab. The recommendation comes as part of a suite of recommendations published in the British Medical Journal . The two therapies designed to work by binding to the … Full story available on Benzinga.com